KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Inventory (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Inventory for 9 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 79.6% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 79.6% year-over-year, with the annual reading at $2.3 million for FY2025, 79.6% down from the prior year.
  • Inventory hit $2.3 million in Q4 2025 for Bionano Genomics, down from $7.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $33.1 million in Q1 2023 to a low of $2.3 million in Q4 2025.
  • Historically, Inventory has averaged $16.4 million across 5 years, with a median of $15.3 million in 2022.
  • Biggest five-year swings in Inventory: soared 435.84% in 2022 and later tumbled 79.6% in 2025.
  • Year by year, Inventory stood at $12.4 million in 2021, then surged by 140.26% to $29.8 million in 2022, then dropped by 23.08% to $22.9 million in 2023, then plummeted by 51.42% to $11.1 million in 2024, then crashed by 79.6% to $2.3 million in 2025.
  • Business Quant data shows Inventory for BNGO at $2.3 million in Q4 2025, $7.0 million in Q3 2025, and $8.6 million in Q2 2025.